Tesetaxel
- Generic Name
- Tesetaxel
- Drug Type
- Small Molecule
- Chemical Formula
- C46H60FN3O13
- CAS Number
- 333754-36-2
- Unique Ingredient Identifier
- UG97LO5M8Y
- Background
Tesetaxel has been used in trials studying the treatment of Cancer, Melanoma, Prostate Cancer, Gastric Carcinoma, and Advanced Melanoma, among others.
Tesetaxel for Previously Treated Patients With Bladder Cancer
- Conditions
- Carcinoma, Transitional Cell
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 33
- Registration Number
- NCT01215877
- Locations
- ๐ฎ๐น
San Camillo Forlanini Hospital, Rome, Italy
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธThomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT01170975
- Locations
- ๐บ๐ธ
DaVita Clinical Researh, Minneapolis, Minnesota, United States
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
- Conditions
- Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric Junction
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT01095120
- Locations
- ๐ฐ๐ท
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
๐บ๐ธNorthwestern Medical Faculty Foundation, Chicago, Illinois, United States
๐บ๐ธAbramson Cancer of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
- Conditions
- Melanoma
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT01092585
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Tesetaxel in Metastatic Melanoma
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01064713
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT00080834
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
๐บ๐ธUniversity of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT00077077
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธCancer Therapy and Research Center, San Antonio, Texas, United States
๐บ๐ธBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.